Infinedi Taps Former Accenture VP to Lead AI-Driven Expansion

Infinedi, a healthcare artificial intelligence company specializing in medical imaging automation, announced Monday it has hired Rohan Arora as Chief Revenue Officer — a signal the company is gearing up for a major enterprise sales push as it looks to expand beyond its radiology roots into broader clinical workflow automation.

Arora comes from Accenture, where he spent over a decade building enterprise sales operations and leading client relationships across healthcare, financial services, and technology sectors. His most recent role was Vice President of Sales for Accenture's North American healthcare practice, where he oversaw client acquisition and revenue growth for digital transformation projects.

The hire comes at a pivotal moment for Infinedi. The company has built a reputation automating radiology workflows — flagging abnormalities in X-rays, CT scans, and MRIs to help radiologists prioritize urgent cases — but that market is getting crowded. Competitors like Aidoc, Viz.ai, and Annalise.ai have raised hundreds of millions collectively, and health systems are becoming pickier about which AI tools actually improve throughput versus adding noise.

Infinedi's bet is that the next growth phase isn't just better radiology AI — it's embedding AI across the entire clinical documentation and decision-support stack. That requires selling to C-suite executives and IT leaders who control hospital-wide technology budgets, not just department heads. That's where Arora's background becomes relevant.

Arora's career trajectory mirrors a broader shift in healthcare technology: the realization that clinical innovation alone doesn't scale without enterprise sales infrastructure. At Accenture, he led teams selling multi-million-dollar digital transformation engagements — the kind of projects that require navigating procurement committees, compliance reviews, and multi-year implementation timelines.

That's a different muscle than the product-led growth strategies common in consumer tech. Healthcare buyers don't swipe credit cards. They run pilot programs, demand peer-reviewed evidence, and need assurance the vendor will still exist in five years when the contract comes up for renewal.

"Rohan brings the kind of strategic selling expertise we need as we move upmarket," said Dr. Arun Kumar, Infinedi's CEO, in the company's announcement. "We're not just selling point solutions anymore. We're selling a vision for how AI reshapes clinical operations — and that requires someone who can speak the language of hospital executives."

Translation: Infinedi is done being a radiology vendor. It wants to be a platform play.

Infinedi isn't alone in chasing the enterprise healthcare AI opportunity. The sector has seen a flood of capital over the past three years, driven by two tailwinds: widespread clinician burnout (exacerbated by the pandemic) and rapid improvements in large language models that can actually read and summarize unstructured clinical notes.

According to Rock Health, digital health companies raised $10.7 billion in 2025, with AI-enabled clinical tools capturing roughly 18% of that total. The largest deals went to companies automating administrative workflows — prior authorization, claims processing, clinical documentation — rather than diagnostic imaging alone.

That shift reflects a hard truth: health systems care more about reducing administrative overhead than they do about marginal improvements in diagnostic accuracy. A tool that saves nurses 30 minutes per shift on charting is worth more, operationally, than an AI that flags lung nodules radiologists were already going to catch.

Infinedi hasn't disclosed its latest funding round or valuation, but the company has been operating in relative stealth compared to better-capitalized rivals. That makes Arora's hire even more telling — it suggests the company is prioritizing revenue execution over another fundraising cycle, at least for now.

Arora's mandate is clear: build a repeatable enterprise sales motion that can land six- and seven-figure contracts with integrated delivery networks (IDNs) and academic medical centers. That means assembling a team that can manage 12-to-18-month sales cycles, navigate value-based care incentives, and demonstrate ROI in terms hospital CFOs actually care about — labor cost reduction, length of stay, readmission rates.

Infinedi's core product suite centers on AI-powered medical imaging analysis, primarily in radiology. The platform ingests diagnostic images — X-rays, CT scans, MRIs — and uses computer vision models to flag abnormalities, prioritize worklists, and surface cases that need urgent review.

The workflow looks like this: a patient gets a chest X-ray in the emergency department. The image is sent to the radiology PACS (picture archiving system). Infinedi's AI runs in the background, analyzes the image in real time, and tags it if it detects signs of pneumothorax, pulmonary edema, or other time-sensitive findings. That moves the case to the top of the radiologist's queue.

It's not diagnostic AI in the regulatory sense — the company doesn't claim to replace radiologists. It's triage AI, designed to make existing radiologists faster and reduce the time between imaging and clinical action.

That's table stakes now. The more interesting question is what comes next.

According to sources familiar with the company's product roadmap, Infinedi is working on ambient clinical documentation tools that transcribe and summarize physician-patient conversations — similar to what Abridge and Nuance's DAX Copilot already do — but with tighter integration into imaging workflows. The idea: a doctor orders a scan, discusses findings with the patient, and the AI generates both the radiology report and the clinical note simultaneously, pulling relevant prior imaging history automatically.

Here's the part that doesn't make it into press releases: healthcare AI companies live or die based on EHR integration quality. If your tool requires clinicians to log into a separate dashboard, copy-paste findings, or manually trigger workflows, adoption craters. Physicians won't use it, no matter how accurate the AI.

Epic and Cerner (now Oracle Health) control roughly 70% of the U.S. hospital EHR market. Both have their own AI initiatives and aren't exactly enthusiastic about third-party tools that don't play nicely with their ecosystems. Infinedi will need partnerships or integration frameworks that make its AI feel native inside Epic's workflow engine — not bolted on.

Arora's hiring reflects a broader talent migration happening across healthcare technology: executives from Accenture, Deloitte, McKinsey, and other consulting giants are moving into operational roles at startups and growth-stage companies.

The reason? Healthcare buyers trust people who've sold to them before. A VP from Accenture has existing relationships with CIOs and COOs at major health systems. They know how to structure value-based contracts, navigate procurement, and manage implementations that span dozens of hospitals.

That matters more than deep technical expertise when you're selling AI to hospitals. The technology is increasingly commoditized — most clinical AI models hit similar accuracy benchmarks. The differentiator is go-to-market execution: Can you get a pilot approved? Can you scale from one hospital to an entire system? Can you prove ROI in a way that survives budget scrutiny?

Consulting veterans know how to do that. Product founders often don't.

Even with strong sales leadership, Infinedi faces the same revenue model headwinds as every other healthcare AI vendor: hospitals want to pay per value delivered, not per license. They want risk-sharing agreements where the vendor only gets paid if readmissions drop or imaging turnaround times improve.

That creates a unit economics problem. Traditional SaaS companies charge annual recurring revenue based on seats or usage. Healthcare AI companies increasingly have to tie pricing to clinical outcomes they don't fully control — because the hospital's staffing levels, patient acuity, and existing workflows all influence results.

Infinedi hasn't disclosed which pricing model it uses, but Arora's background in complex deal structuring suggests the company may move toward hybrid models that blend recurring fees with performance incentives. That's harder to execute but aligns vendor and buyer incentives — and makes renewals stickier.

The question is whether Infinedi's margin profile can sustain that model at scale, especially if it's still burning capital to build out new product lines.

Arora's hire sets up two possible trajectories for Infinedi over the next 18 months.

Path one: the company executes on enterprise sales, lands a few marquee health system contracts, and uses that traction to raise a significant growth round — likely $50 million or more — to fund product expansion and compete head-to-head with better-capitalized rivals.

Path two: Infinedi becomes an acquisition target. The healthcare AI market is consolidating. Larger players like Philips, GE HealthCare, and Siemens Healthineers are buying AI companies to integrate into their imaging hardware and enterprise software suites. A company with solid radiology AI, early traction in clinical documentation, and a proven enterprise sales leader could be attractive at the right price.

Either way, the hire signals Infinedi is done being a feature — it's trying to become a platform. Whether it has the capital, product differentiation, and market timing to pull that off is the story to watch.